— Maja Lindenmeyer, PhD
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
©Maja Lindenmeyer, created with BioRender
Our group represents the core facility of the “European Renal cDNA Bank-Kroener Fresenius Biopsy Bank” (ERCB-KFB), a multicenter study for gene expression analysis in different human renal diseases, and the “Hamburg and European Renal Omics Bank” (HERO), a collaborative project for conducting translational research in human renal diseases. Using state-of-the art Omics and non-Omics technologies we aim to
III. Department of Medicine, University Medical Center Hamburg-Eppendorf (UKE)
Martinistr. 52
20246 Hamburg, Germany
since 2022 | Principal Investigator / Co-Coordinator BMBF STOP-FSGS |
since 2022
|
Principal Investigator BMBF UPTAKE |
since 2021
|
Project Leader/ Study Coordinator of the Hamburg and European Renal Omics Biobank (HERO) |
since 2018
|
Laboratory head, III. Department of Medicine, UKE, Prof. Dr. T. B. Huber |
since 2018 | Coordinator of the ERCB |
1994 – 2000
|
Chemistry, Technical University Karlsruhe, University of Freiburg |
2014 - 2020
|
Habilitation in Molecular Nephrology, University of Zurich (Switzerland) |
2004
|
PhD, Department of Pharmaceutical Biology and Biotechnology, University of Freiburg |
2000
|
Diploma in Chemistry, University of Freiburg |
2015 – 2018
|
Junior Group leader, Nephrology Center, IV. Department of Medicine, University Hospital of Munich (LMU) |
2012 – 2018
|
Deputy-Coordinator of the European Renal cDNA Bank-Kroener Fresenius |
2010 – 2014
|
Laboratory Head of the Nephrology Lab Zurich, University of Zurich (Switzerland) |
2008 – 2010
|
Postdoctoral Fellow, Institute of Physiology and Division of Nephrology, University of Zurich (Switzerland), Prof. Dr. C. Cohen |
2006 – 2007
|
Postdoctoral Fellow, Nephrology Center, IV. Deparment of Medicine, University Hospital of Munich (LMU), Prof Dr. C. Cohen |
2004 – 2005
|
Postdoctoral Fellow, School of Biological Sciences, Queen Mary College, London (UK), Prof. Dr. M. Warren |
2010 - 2020
|
Habilitation Scholarship of the Holcim Foundation |
2004 – 2005
|
Post-Doc fellowship of the German Academic Exchange Service (DAAD) |
2001 – 2003
|
PhD fellowship of the “Landesgraduiertenförderung Baden-Württemberg” |
1. | Molecular consequences of SARS-CoV-2 liver tropism. |
2. | Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting. |
3. | Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice. |
4. | SARS-CoV-2 renal tropism associates with acute kidney injury. |
5. | ADAM10-Mediated Ectodomain Shedding Is an Essential Driver of Podocyte Damage. |
6. | Dysregulated mesenchymal PDGFR-β drives kidney fibrosis |
7. | Multiorgan and Renal Tropism of SARS-CoV-2. |
8. | Tubular NOX4 expression decreases in chronic kidney disease but does not modify fibrosis evolution. |
9. | Metabolic pathways and immunometabolism in rare kidney diseases. |
10. | Transcriptome-based network analysis reveals renal cell type-specific dysregulation of hypoxia-associated transcripts. *contributed equally |
Martinistraße 52
Campus Research N27
20246 Hamburg Germany
This email address is being protected from spambots. You need JavaScript enabled to view it.